Ruzanna Papyan: I suggest delving into the critical management of adverse events associated with dinutuximab beta
Ruzanna Papyan shared on LinkedIn:
“Week 3 of the Global Access To Anti GD2 Campaign:
This week, I suggest delving into the critical management of adverse events associated with dinutuximab beta, a key anti-GD2 therapy, used in treating high-risk neuroblastoma.
In a 2021 publication in Pediatric Drugs, practical guidance was provided on managing adverse events linked with dinutuximab beta.
Despite the treatment’s efficacy in improving survival rates, it is associated with several challenging side effects, such as pain, fever, hypersensitivity reactions, and capillary leak syndrome.
Managing these adverse events is crucial for the successful administration of dinutuximab beta. The recommendations include:
- Pain Management: Utilizing a combination of non-opioid analgesics, gabapentin, and morphine to control treatment-related pain effectively.
- Fever: Implementing prophylactic antipyretics and monitoring for potential infections.
- Hypersensitivity Reactions: Pre-treatment with antihistamines and careful monitoring during infusions to mitigate allergic responses.
- Capillary Leak Syndrome: Regular blood pressure and weight monitoring, with fluid management strategies tailored to symptom severity.
These guidelines are vital for ensuring that children with high-risk neuroblastoma receive the full benefit of dinutuximab beta with minimal toxicity, thereby improving their chances of survival and quality of life.
For those interested in learning more about this critical guidance, you can access the full paper.
By advocating for the inclusion of anti-GD2 therapies in the World Health Organization Essential Medicines List, we can help make these life-saving treatments accessible to children worldwide.
Join us in our mission to enhance global access to these critical therapies. Your support, knowledge sharing, and advocacy are key to changing lives. Let’s give every child the future they deserve.”
Source: Ruzanna Papyan/LinkedIn
Ruzanna Papyan is a pediatric oncologist and clinical research physician at the Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after Prof. Yeolyan. .
She is also Head of the Musculoskeletal Multidisciplinary Working Group and Assistant Professor at the Department of Pediatric Oncology and Hematology at Yerevan State Medical University.
Dr. Papyan coordinates educational sessions for the Global Neuroblastoma Network and holds the esteemed position of co-chair of the Adolescents and Young Adults Steering Group at the International Society of Paediatric Oncology (SIOP).
She is a member of oncology societies, such as AAHO, SOHO, ESMO, ESO, and POEM. Her research interests include soft tissue and bone sarcomas, and neuroblastomas among children and young adults.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023